• Innoviva unit Innoviva Specialty Therapeutics struck an exclusive distribution and licensing deal with Dr. Reddy’s for XACDURO in select international markets.
• Rights cover South and Central America, the Caribbean, Russia, and CIS; Dr. Reddy’s will run development, regulatory filings, commercialization.
• Innoviva Specialty Therapeutics kept XACDURO rights outside the licensed territory; eligible for an upfront payment, milestones, tiered royalties on net sales.
• XACDURO is a US-approved IV antibiotic for HABP/VABP caused by susceptible Acinetobacter; FDA clearance came in May 2023.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Innoviva Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260616536715) on June 16, 2026, and is solely responsible for the information contained therein.